Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Primary Fibromyalgia
Interventions: GRT9906, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: DeLand, Florida • Charlotte, North Carolina • Medford, Oregon + 2 more

Conditions: Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neuropathy; Radicular, Lumbar, Lumbosacral, Failed Back Surgery Syndrome, Spinal Stenosis, Herniated Disc
Interventions: Pregabalin, Sugar Pill; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: MT-501; Drug
Lead sponsor: Mirador Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Coronary Artery Disease
Interventions: Omacor, omega-3 fatty acids in CAD patients; Drug
Lead sponsor: HeartDrug Research LLC; Other
Eligibility: 50 Years to 60 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Peyronie Disease, Sexual Dysfunction, Physiological, Sexual Dysfunction Male, Genital Diseases, Male
Interventions: Autologous Platelet-Rich Plasma (PRP), Placebo (Normal Saline); Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lactose Intolerance
Interventions: Lactobacillus acidophilus MPH734, Placebo; Dietary Supplement
Lead sponsor: Lemuel W. Taylor IV; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Belton, Texas

Conditions: Cardiovascular Disease, Vitamin D Deficiency
Interventions: Vitamin D3, Placebo; Dietary Supplement
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Depression, Depression, Anxiety, Inflammation
Interventions: Freeze Dried Blueberry Powder - 71717, USHBC Blueberry Placebo Formula #114; Dietary Supplement
Lead sponsor: Louisiana State University, Baton Rouge; Other
Eligibility: 18 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Cottonport, Louisiana • Marksville, Louisiana

Conditions: Eosinophilic Esophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more

Conditions: Cocaine Dependence
Interventions: Doxazosin, Modafinil, cocaine, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Cough
Interventions: ADX-629, Placebo; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: San Diego, California • San Jose, California • Hollywood, Florida + 11 more

Conditions: Stress Disorders, Post-Traumatic, Combat Disorders, Sleep Disorders
Interventions: prazosin hydrochloride, placebo; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions: Olanzapine, Amantadine, Olanzapine and placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Pharmacokinetics, Safety, Tolerability
Interventions: 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo; Drug
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Sudden Sensorineural Hearing Loss
Interventions: Statin, methylprednisolone, dexamethasone, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Breast Cancer
Interventions: ABT-869, paclitaxel, Placebo for ABT-869; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: San Francisco, California • Harvey, Illinois

Conditions: Autism Spectrum Disorder (ASD)
Interventions: Omega-3 Fatty Acid; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dental Caries
Interventions: C16G2, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Indianapolis, Indiana • Kalispell, Montana • New York, New York + 2 more

Conditions: Smoking Cessation
Interventions: Bupropion SR, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Post-Amputation Phantom Limb Pain
Interventions: Cryoneurolysis, Sham Comparator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • San Diego, California • Gainesville, Florida + 2 more

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Malignant Glioma
Interventions: Nuvigil®, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Efficacy of Pregabalin in Patients With Radicular Pain

A First-in-Human Single and Multiple Ascending Dose Study of MT-501

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

PRP for Treatment of Peyronie's Disease

Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo

Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D

Effect of Whole Blueberry Powder Consumption on Depression in a Central Louisiana Population

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Complementary Combination Therapy for Cocaine Dependence

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

Oral Statins and Protection From Hearing Loss

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy

Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma